Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
RESEARCH TOOLSreports
Apellis Pharmaceuticals (APLS) Stock Price & Analysis
732 Followers
APLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.83 - $94.75
Previous Close$49.86
Volume6.67M
Average Volume (3M)1.32M
Market Cap
$6.01B
Enterprise Value$5.77B
Total Cash (Recent Filing)$351.20M
Total Debt (Recent Filing)$110.93M
Price to Earnings (P/E)-11.1
Beta0.53
Next Earnings
May 07, 2024EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.48
Shares Outstanding120,581,749
10 Day Avg. Volume1,253,811
30 Day Avg. Volume1,320,963
Standard Deviation0.21
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)30.91
Price to Sales (P/S)39.41
Price to Cash Flow (P/CF)-15.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.75
Enterprise Value/Gross Profit14.79
Enterprise Value/Ebitda-11.17
Forecast
1Y Price Target
$82.92Price Target Upside87.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Apellis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Market ExpansionIncreased use of both Syfovre and Izervay primarily comes from doctors practicing in community settings, suggesting market expansion in those areas.
Regulatory UpdateAnalyst's recommendation to buy is based on the expectation that the European Medicines Agency will eventually recognize the functional benefit of pegcetacoplan for GA patients and grant approval.
Sales GrowthAstellas projects significant sales growth for Izervay in the upcoming fiscal year, with expectations to capture about 40% of the total GA patient market share.
Bears Say
Market CompetitionSyfovre's usage is expected to decline due to the new J-code for Izervay, which facilitates easier reimbursement and could shift prescribing patterns.
Regulatory ChallengesThe MAA review for Syfovre will be led by the same rapporteurs that previously led to a negative opinion, which could imply persistent challenges.
Safety ConcernsConcerns over the risk of retinal vasculitis with Syfovre use have been noted by a key opinion leader.
---
Ownership Overview
15.03% Insiders
37.84% Mutual Funds
14.96% Other Institutional Investors
32.16% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $19.83 and its highest was $94.75 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is May 07, 2024 which is in 7 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Feb 27, 2024. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.731 by $0.001.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -$0.46.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 120,581,750 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.731. Following the earnings report the stock price went down -3.318%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Driehaus Capital Management LLC. It holds Apellis Pharmaceuticals Inc’s shares valued at 29M.
---
Apellis Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.92 (87.64% Upside)
$82.92 (87.64% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-42.65%
12-Months-Change
Fundamentals
Return on Equity
-290.14%
Trailing 12-Months
Asset Growth
3.75%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
---
APLS Company Deck
---
APLS Earnings Call
Q4 2024
0:00 / 0:00
---
APLS Stock 12 Months Forecast
Average Price Target
$82.92
▲(87.64% Upside)
Technical Analysis
Best Analysts Covering APLS
1 Year
1 Year Success Rate
19/29 ratings generated profit
1 Year Average Return
+19.75%
reiterated a buy rating 3 months ago
Copying Justin Kim's trades and holding each position for 1 Year would result in 65.52% of your transactions generating a profit, with an average return of +19.75% per trade.
---